Prosecution Insights
Last updated: April 19, 2026
Application No. 17/925,434

NOVEL FLUORESCENT COMPOUNDS FOR LABELING TUMOR TISSUE

Final Rejection §102§112
Filed
Nov 15, 2022
Examiner
WESTERBERG, NISSA M
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Proimaging
OA Round
2 (Final)
23%
Grant Probability
At Risk
3-4
OA Rounds
4y 3m
To Grant
60%
With Interview

Examiner Intelligence

Grants only 23% of cases
23%
Career Allow Rate
210 granted / 896 resolved
-36.6% vs TC avg
Strong +37% interview lift
Without
With
+36.9%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
67 currently pending
Career history
963
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
42.9%
+2.9% vs TC avg
§102
10.9%
-29.1% vs TC avg
§112
26.9%
-13.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 896 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed December 15, 2025, have been fully considered but they are not deemed to be fully persuasive. The following rejections and/or objections constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 112 – Failure to Further Limit The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 15 was rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. This rejection is MAINTAINED for the reasons of record set forth in the Office Action mailed August 21, 2025 and those set forth herein. Applicants traverse this rejection on the grounds that claim 15 is amended to correct the noted informality and claimed claim 15 incorporates all the limitations of claim 11 and compound 36 falls within the scope of claim 11. These arguments are unpersuasive. Compound 39 was deleted from claim 15 but compound 36 is still present. Compound 36 still does not fall within the scope of claim 11 as R”11 as set forth in claim 11 must comprise an aryl or heteroaryl ring and the 6 membered carbocyclic ring with two double bonds in compound 36 is not an aryl or heteroaryl ring. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 11 was rejected under 35 U.S.C. 102(a)(1) as being anticipated by Fabricius et al. (US 5,519,145; cited on IDS filed 3/21/25). This rejection is MAINTAINED for the reasons of record set forth in the Office Action mailed August 21, 2025 and those set forth herein. Applicants traverse on the grounds that the revised scope of claim 11 no longer reads on the compounds from Fabricius. These arguments are unpersuasive. The cited compounds D-21, D-23 and D-25 of Fabricius et al. had –(CH2)4SO3- for R1 present off the ring nitrogen atoms, at least one carboxylic acid group is present (R4) (see end of instant claim 11), a non-hydrogen substituent for at least one of instant R1 – R6 as R6 = SO3- and sodium counterions are present (Q). The claim still requires at least one of R1 – R6 to not be hydrogen and one R1, R2, R4 and R5 can be SO3- with a sodium counterion. Y” is actually now broader than before but still can be COOR’10. The amended range for n1 and n2 is narrower but 3 is still a permitted value and the compounds still meet the limitation of R7 and R8 being a C1 alkyl (methyl) group. Therefore claim 11 as amended is still anticipated by the cited compounds of Fabricius et al. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nissa M Westerberg whose telephone number is (571)270-3532. The examiner can normally be reached M - F 8 am - 4 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Nissa M Westerberg/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Nov 15, 2022
Application Filed
Aug 20, 2025
Non-Final Rejection — §102, §112
Dec 15, 2025
Response Filed
Jan 28, 2026
Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12539279
SUPRAMOLECULAR IONIZABLE LIPID MOLECULES WITH HETEROATOMIC TUNING FOR NUCLEIC ACID DELIVERY
2y 5m to grant Granted Feb 03, 2026
Patent 12522579
MONOAMINE OXIDASE B IMAGING PROBE
2y 5m to grant Granted Jan 13, 2026
Patent 12509458
[18F]-LABELED IMIDAZOPYRIDINE DERIVATIVES AS PET RADIOTRACER
2y 5m to grant Granted Dec 30, 2025
Patent 12498375
WATER-SOLUBLE COMPOUND FOR DETECTION OF BETA-AMYLOID
2y 5m to grant Granted Dec 16, 2025
Patent 12484883
FUNCTIONALIZED SUPERABSORBENT MATERIAL FOR USE IN LESION PHANTOM
2y 5m to grant Granted Dec 02, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
23%
Grant Probability
60%
With Interview (+36.9%)
4y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 896 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month